Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V. (NASDAQ:MYL), announced the launch of three generic products in Canada for the treatment of HIV.
As quoted in the press release:
One of the products is Mylan-Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg, a generic alternative to Truvada®.
Mylan received final approval from Health Canada for this product and for Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla®; and Mylan-Tenofovir Disoproxil 300 mg, a generic alternative to Viread®.
Mylan’s Chief Commercial Officer Tony Mauro said, “Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world, and today marks another milestone in those efforts. More than 40% of people worldwide being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day, and we’re proud to further expand access to such medicines in Canada.”